Litcius/Paper detail

Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Platform to Study SARS-CoV-2 Related Myocardial Injury

Chun‐Ka Wong, Hayes K. H. Luk, Wing‐Hon Lai, Yee‐Man Lau, Ruiqi Zhang, Antonio C. P. Wong, George Chi-Shing Lo, Kwok‐Hung Chan, Ivan Fan-Ngai Hung, Hung‐Fat Tse, Patrick C. Y. Woo, Susanna K. P. Lau, Chung‐Wah Siu

2020Circulation Journal52 citationsDOIOpen Access PDF

Abstract

BACKGROUND: SARS-CoV-2 infection is associated with myocardial injury, but there is a paucity of experimental platforms for the condition. METHODS AND RESULTS: Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) infected by SARS-CoV-2 for 3 days ceased beating and exhibited cytopathogenic changes with reduced viability. Active viral replication was evidenced by an increase in supernatant SARS-CoV-2 and the presence of SARS-CoV-2 nucleocaspid protein within hiPSC-CMs. Expressions of BNP, CXCL1, CXCL2, IL-6, IL-8 and TNF-α were upregulated, while ACE2 was downregulated. CONCLUSIONS: Our hiPSC-CM-based in-vitro SARS-CoV-2 myocarditis model recapitulated the cytopathogenic effects and cytokine/chemokine response. It could be exploited as a drug screening platform.

Topics & Concepts

Induced pluripotent stem cellSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Stem cellCell injuryMedicine2019-20 coronavirus outbreakMyocyteVirologyInternal medicineBiologyCell biologyEmbryonic stem cellDiseaseGeneticsInfectious disease (medical specialty)ApoptosisOutbreakGenePluripotent Stem Cells ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research
Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Platform to Study SARS-CoV-2 Related Myocardial Injury | Litcius